Though in its early stages, NeuroPhage Pharmaceuticals pre-clinical data released recently seems promising when it comes to targeting alpha-synuclein.
I’m obviously not a doctor, or someone with extensive medical training, so don’t hold me to my word.
What’s alpha synulcein? Dad explained to me once as a clumped protein that all Parkinson’s patients have. Parkinson’s and Alzheimer’s patients have clumped proteins, which Dad says are the “bad boys.” So if you can unclump the proteins, could you cure the disease? I don’t know, but it’s worth looking into I’d say.
While there remain questions as to whether alpha-synuclein plays a direct causative role in PD, targeting its aggregation has been of major interest to researchers aiming to develop disease-modifying drugs.
While this study still has to do pre-clinical stuff before even getting to the actual trials, seems like this is a good step in the right direction.
The MJFF awarded funds to this study, which means our fundraising efforts can continue to help. Especially since 88 cents of each dollar donated to the foundation goes directly to research. And currently with the Brin Wojcicki Challenge in effect through the end of the year, those gifts could be doubled.